SenoRx, a developer of medical devices for the diagnosis and treatment of breast cancer, priced 5.5 million shares at $8, a -33% discount to the midpoint of the original $11-$13 range. The company is hoping to gain share in the fragmented $1 billion breast care market and plans to introduce a new therapeutic product in 1Q08. Banc of America, Citigroup, Cowen and Canaccord Adams were the underwriters on the deal. Expect the stock to begin trading on the NASDAQ today under the symbol "SENO."
